Bristol-Myers Squibb Company Ce cash flow to debt ratio of 28.91% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Bristol-Myers Squibb Company Ce's free cash flow has decreased 7.87% from $13.94B last year to $12.85B, signaling decreasing performance

Bristol-Myers Squibb Company Ce's debt to equity ratio is 3.29, which means that the company's assets are unhealthy financed, signaling financial risk.

Bristol-Myers Squibb Company Ce's debt has increased relative to shareholder equity from 3.13 last year to 3.29 today, signaling weakened financials

Bristol-Myers Squibb Company Ce has a net debt to EBITDA ratio of 1.99x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bristol-Myers Squibb Company Ce's interest coverage ratio of 7.01 indicates that earnings with good margin can cover interest payments on company debt

Bristol-Myers Squibb Company Ce's profit margin was -18.53% last year and is 26.48% this year, signaling increasing performance

Bristol-Myers Squibb Company Ce's short-term assets of $29.39B exceed its short-term liabilities of $23.42B

Bristol-Myers Squibb Company Ce's return on assets of 11.40% is higher than the 5.00% threshold, indicating efficient asset utilization

Bristol-Myers Squibb Company Ce's return on equity of 61.86%, is higher than 15.00%, indicating good performance

Bristol-Myers Squibb Company Ce's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bristol-Myers Squibb Company Ce has insufficient public price history to evaluate earnings stability.

Bristol-Myers Squibb Company Ce has positive free cash flow, indicating the company generates cash after capital expenditures

Bristol-Myers Squibb Company Ce has a free cash flow yield of 5.29K%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bristol-Myers Squibb Company Ce's yearly earnings has increased 178.83% since last year from $-8.95B to $7.05B, signaling increasing performance

Bristol-Myers Squibb Company Ce's yearly revenue has decreased 0.22% since last year from $48.30B to $48.19B, signaling decreasing performance

ROIC 13.62% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Bristol-Myers Squibb Company Ce's 3-year revenue CAGR of 1.45% is positive, indicating growing revenue over the past 3 years

Bristol-Myers Squibb Company Ce had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Bristol-Myers Squibb Company Ce has insufficient public price history to evaluate ROE consistency.

Bristol-Myers Squibb Company Ce is undervalued relative to its fair value price of 76.83 based on Base Cash Flow Valuation (DCF) model

Bristol-Myers Squibb Company Ce has an earnings yield of 4.64K%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Bristol-Myers Squibb Company Ce is undervalued relative to its fair value price of 47.27 based on Base EBITDA Valuation model

Bristol-Myers Squibb Company Ce has an EV/EBITDA ratio of 2.00x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bristol-Myers Squibb Company Ce has insufficient data to evaluate this check.

Bristol-Myers Squibb Company Ce had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Bristol-Myers Squibb Company Ce has a price-to-book ratio of 0.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bristol-Myers Squibb Company Ce has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue